LK-1 (by LYKERA biomed)

Lykera Biomed is a privately held biotech company based in Barcelona, Spain

LK-1 (by LYKERA biomed)

Lykera Biomed is a privately held biotech company based in Barcelona, Spain
Institution: LEITAT
Research group: Health and Biomedicine
Principal investigator: Francesc Mitjans

The Problem

A tumor mass is not only formed by proliferating cancer cells, but also receives nutrients via angiogenesis, gets support from surrounding stroma, and shares signalling factors with accessory cells. Therefore there are at least four tumor compartments that keep a constant crosstalk to allow cancer growth and dissemination through metastasis. A key molecule controlling this crosstalk is the alarmin S100A4 (a soluble factor that is absent in normal tissues, but is overexpressed in aggressive cancers).
LYKERA’s scientists have generated a neutralizing antibody against S100A4 and proved that this first-in-class antibody blocks tumor progression and metastatic dissemination in several cancer indications, specially in the devastating, currently incurable, pancreatic cancer. Lykera’s most advanced product, LK-1 has already the in vivo preclinical proof-of-principle and it is ready to enter regulatory preclinical phases.

The Solution

The Solution

LYKERA’s scientists have generated a neutralizing antibody against S100A4 and proved that this first-in-class antibody blocks tumor progression and metastatic dissemination in several cancer indications, specially in the devastating, currently incurable, pancreatic cancer. Lykera’s most advanced product, LK-1 has already the in vivo preclinical proof-of-principle and it is ready to enter regulatory preclinical phases.

Purpose

Development of biologics for the treatment of cancer by targeting not only the tumour cells but also the stromal cells and tumour angiogenesis.
Time to market: 5-10 years
Looking for: Investment for the preclinical regulatory and the clinical phase
Technology: Others
Area: Therapeutics
TRL: 4